Core Viewpoint - Recordati's subsidiary in China, Ruikangdi, has officially filed for deregistration, marking its complete exit from the Chinese market, which will result in the discontinuation of several rare disease medications, including the only oral drug for Cushing's syndrome, Osilodrostat [1][3]. Group 1: Company Actions - Ruikangdi's exit from the Chinese market will lead to the cessation of supply for its rare disease drugs, significantly impacting patients reliant on these medications [1]. - Osilodrostat was approved in China in September 2024 and commercialized in April 2025, but has been available since 2021 as part of a pilot program in Boao Lecheng [3]. Group 2: Patient Impact - The withdrawal of Ruikangdi is seen as a critical loss for Cushing's syndrome patients, as Osilodrostat is considered a "lifesaving drug" [3]. - A patient who has been on Osilodrostat for four years reported spending approximately 1 million yuan on the medication [3]. Group 3: Market Dynamics - Osilodrostat's price in China is around 8,000 yuan per box, with an average annual treatment cost of about 200,000 yuan, despite being one of the lowest-priced markets globally [3]. - The drug was expected to be included in the national medical insurance directory, which would have reduced out-of-pocket costs for patients to below 2,000 yuan per month, but it ultimately was not included [3]. Group 4: Industry Challenges - The high cost of developing rare disease drugs and the limited patient population make pricing and reimbursement a significant challenge, particularly in China where commercial insurance is still developing [4]. - The market for rare disease drugs is further complicated by the fact that only about 50 patients in China have purchased Osilodrostat, indicating low market penetration [4]. - The exit of Recordati is not an isolated incident, as other companies like BioMarin have also withdrawn rare disease treatments from the Chinese market, highlighting the difficulties faced by small to mid-sized firms in this sector [4][5].
又一款罕见病药将退出中国市场
Xin Lang Cai Jing·2026-01-17 15:37